• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.

作者信息

Xu Wei-lai, Jin Jie, Qian Wen-bin

机构信息

Institute of Hematology, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.

出版信息

Chin Med J (Engl). 2010 Jan 5;123(1):108-10.

PMID:20137586
Abstract
摘要

相似文献

1
Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
Chin Med J (Engl). 2010 Jan 5;123(1):108-10.
2
[Curative effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome].小剂量阿糖胞苷联合阿克拉霉素与粒细胞集落刺激因子预激（CAG方案）治疗中高危骨髓增生异常综合征患者的疗效
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Apr;35(4):370-3. doi: 10.3969/j.issn.1672-7347.2010.04.015.
3
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.采用伊达比星、阿糖胞苷、依托泊苷及粒细胞集落刺激因子预激进行强化化疗治疗晚期骨髓增生异常综合征和高危急性髓系白血病患者。
Ann Hematol. 2004 Aug;83(8):498-503. doi: 10.1007/s00277-004-0889-0. Epub 2004 May 20.
4
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.低剂量阿糖胞苷与依托泊苷联合化疗用于高危骨髓增生异常综合征及其白血病期：一项初步研究。
Cancer. 1996 Aug 1;78(3):422-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<422::AID-CNCR7>3.0.CO;2-L.
5
A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes.
Leuk Res. 1993 Aug;17(8):629-32. doi: 10.1016/0145-2126(93)90066-t.
6
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.拓扑替康与阿糖胞苷联合及其他强化化疗方案治疗骨髓增生异常综合征的长期随访结果
Cancer. 2006 Mar 1;106(5):1099-109. doi: 10.1002/cncr.21699.
7
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.持续静脉输注柔红霉素和阿糖胞苷用于诱导高危急性髓性白血病和骨髓增生异常综合征缓解
Neth J Med. 1990 Feb;36(1-2):19-24.
8
Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.含中剂量阿糖胞苷方案的强化诱导化疗治疗初治急性髓系白血病
Am J Hematol. 2009 Jul;84(7):422-7. doi: 10.1002/ajh.21441.
9
[WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
Rinsho Ketsueki. 2002 Oct;43(10):960-2.
10
Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.小剂量阿糖胞苷联合阿克拉霉素并联合粒细胞集落刺激因子预激（CAG方案）对老年急性髓系白血病患者预后的影响。
Leuk Res. 2007 Oct;31(10):1383-8. doi: 10.1016/j.leukres.2007.02.009. Epub 2007 Apr 8.

引用本文的文献

1
Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.阿克拉霉素：作用机制、毒性、药代动力学和临床地位的现代认识。
Cancer Chemother Pharmacol. 2024 Aug;94(2):123-139. doi: 10.1007/s00280-024-04693-1. Epub 2024 Jul 4.
2
Cephalotaxus Alkaloids.三尖杉生物碱
Alkaloids Chem Biol. 2017;78:205-352. doi: 10.1016/bs.alkal.2017.07.001. Epub 2017 Aug 16.
3
Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.
高三尖杉酯碱联合阿糖胞苷及阿克拉霉素治疗骨髓增生异常综合征-难治性贫血伴原始细胞增多患者的疗效与安全性
Oncol Lett. 2016 Jan;11(1):355-359. doi: 10.3892/ol.2015.3876. Epub 2015 Nov 5.